Journal of Rheumatic Diseases

Table. 3.

Comparison of characteristics between non-progressors (ΔmSASSS <1 unit/year) and progressors (ΔmSASSS ≥1 unit/year) among male patients with ankylosing spondylitis (n=85)

Variable Non-progressor (n=52) Progressor (n=33) p-value
Age at disease onset (yr) 25.9±11.8 27.5±8.9 0.507
Age at estrogen sampling (yr) 35.6±12.1 42.6±8.7 0.005
Disease duration (mo) 38.5±40.4 82.4±88.6 0.003
Peripheral arthritis 26 (50.0) 12 (36.4) 0.218
Hip involvement 15 (28.8) 4 (12.1) 0.108
Uveitis 14 (26.9) 9 (27.3) 0.972
Enthesitis 7 (13.5) 5 (15.2) 0.827
mSASSS, initial 3.9±4.8 16.8±13.7 <0.001
mSASSS, final 19.2±21.5 22.0±23.0 0.601
Sacroiliitis grade* 4.90±1.33 6.39±1.61 <0.001
Estrogen (pg/mL) 109.6±36.7 121.1±34.1 0.153
Dkk1 (ng/mL) 1,384.0±823.6 1,022.1±595.0 0.032
Leptin (pg/mL) 1,591.7±1,497.3 2,375.7±2,235.8 0.082
ESR, initial (mm/h) 47.2±34.3 59.3±26.6 0.088
CRP, initial (mg/dL) 2.51±2.96 4.19±4.44 0.039
BMI (kg/m2) 23.4±3.3 26.5±3.7 <0.001
Anti-TNF use 43 (82.7) 31 (93.9) 0.132
Current smoker 17 (32.7) 14 (42.4) 0.364
X-ray follow-up duration (mo) 88.7±58.3 110.6±63.4 0.106

Data are expressed as mean±standard deviation or number (%). mSASSS: modified Stoke Ankylosing Spondylitis Spine Score, Dkk1: dickkopf-1, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, BMI: body mass index, TNF: tumor necrosis factor, E2: 17β-estradiol. *Sacroiliitis grade refers to the sum of sacroiliitis grades of the each sides according to the modified New York criteria. Reference ranges for E2 are 0∼400 pg/mL.

J Rheum Dis 2021;28:76~84 https://doi.org/10.4078/jrd.2021.28.2.76
© J Rheum Dis